Bryan Garnier - Oncimmune Holdings (ONC) ONCIMMUNE: H1 results and imminent ECLS catalyst | Corporate | 140p vs. 130p

Report

Bryan Garnier

Gary Waanders

ONCIMMUNE: H1 results and imminent ECLS catalyst | Corporate | 140p vs. 130p

ONCIMMUNE - Corporate | 140p vs. 130p (+45%)
H1 results and imminent ECLS catalyst

Oncimmune in brief
H1 financial results to Nov 30, 2018 â€“ no surprises
ECLS, largest biomarker-based lung cancer screening trial
Increased valuation on strengthening outlook

13/02/2019 4 EN

Underlying

Oncimmune Holdings

Oncimmune Holdings and its subsidiaries are engaged in cancer diagnosis.

See profile

GB00BYQ94H38 London Stock Exchange United Kingdom

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Gary Waanders

Other Reports on these Companies

Hybridan

Hybridan Small Cap Feast - 21 May 24

21st May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 7th May: Time To ACT plc, an engineering business focused on technology for the energy transition sector, has announced its intention to seek Admission to trading on the Aquis Stock Exchange Growth Market. The Company reports it is revenue generating, prof...

May 21, 2024 May 21, 2024 1 EN

Hybridan

Hybridan Small Cap Feast - 29 Feb 24

29th February 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to...

February 29, 2024 February 29, 2024 1 EN

Hybridan

Hybridan Small Cap Feast - 12 Jul 23

12th July 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to any...

July 12, 2023 July 12, 2023 1 EN

Alfen: large substation contract with TEC

This morning, Alfen announced it has secured a double-digit million euro contract with TEC, one of the three Belgian public transport operators, to deliver customised medium-voltage walk-in substations for its bus fleet electrification in the Walloon region. Under this two-year framework agreement,

10h / 37m 10h / 37m 1 EN

Mahaut Arnaud ... (+3)

Mahaut Arnaud
Paul de Froment
Thomas Mordelle

Carbios: partnership with Tomra Textiles

This morning, Carbios announced it had signed an agreement with Tomra Textiles - a tech venture branch of the sorting technology leader Tomra - to collaborate on creating an efficient system for textile waste collection, sorting and preparation in Northern Europe. Under this agreement Tomra Textile

10h / 43m 10h / 43m 1 EN

Bruno Bulic ... (+2)

Bruno Bulic
Oscar Haffen Lamm

Chikungunya vaccine competitor progressing in-line

Good to know: Bavarian yesterday announced that it completed its Biologic License Application (BLA) with the US FDA for its Chikungunya vaccine CHIKV VLP. Bavarian Nordic’s CHIKV might thus enter the market in H1 2025 if approved by the FDA. We believe the news largely anticipated by the market and

10h / 49m 10h / 49m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONCIMMUNE: H1 results and imminent ECLS catalyst | Corporate | 140p vs. 130p

Hybridan Small Cap Feast - 21 May 24

Hybridan Small Cap Feast - 29 Feb 24

Hybridan Small Cap Feast - 12 Jul 23

Alfen: large substation contract with TEC

Carbios: partnership with Tomra Textiles

Chikungunya vaccine competitor progressing in-line

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe